For the readers interested in the stock health of Infinity Pharmaceuticals Inc. (INFI). It is currently valued at $3.11. When the transactions were called off in the previous session, Stock hit the highs of $3.31, after setting-off with the price of $3.30. Company’s stock value dipped to $3.04 during the trading on the day. When the trading was stopped its value was $3.25.
Recently in News on June 14, 2021, Infinity to Present at The Keystone Symposia Precision Oncology Meeting. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that Dr. Brian Schwartz will present a summary of recent eganelisib clinical data followed by a Q&A session at the Keystone Symposia Precision Oncology: Translating Discovery to the Clinic Meeting taking place on June 21, 2021. You can read further details here
Infinity Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $5.98 on 02/11/21, with the lowest value was $1.91 for the same time period, recorded on 01/06/21.
Infinity Pharmaceuticals Inc. (INFI) full year performance was 248.65%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Infinity Pharmaceuticals Inc. shares are logging -47.99% during the 52-week period from high price, and 298.72% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.78 and $5.98.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4669831 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Infinity Pharmaceuticals Inc. (INFI) recorded performance in the market was 46.70%, having the revenues showcasing -0.32% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 277.38M, as it employees total of 23 workers.
The Analysts eye on Infinity Pharmaceuticals Inc. (INFI)
During the last month, 4 analysts gave the Infinity Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.29, with a change in the price was noted -0.36. In a similar fashion, Infinity Pharmaceuticals Inc. posted a movement of -10.37% for the period of last 100 days, recording 2,911,173 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for INFI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Infinity Pharmaceuticals Inc. (INFI)
Raw Stochastic average of Infinity Pharmaceuticals Inc. in the period of last 50 days is set at 46.02%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.26%. In the last 20 days, the company’s Stochastic %K was 36.06% and its Stochastic %D was recorded 43.58%.
Considering, the past performance of Infinity Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 46.70%. Additionally, trading for the stock in the period of the last six months notably improved by 47.39%, alongside a boost of 248.65% for the period of the last 12 months. The shares increased approximately by -6.61% in the 7-day charts and went down by 2.98% in the period of the last 30 days. Common stock shares were lifted by -0.32% during last recorded quarter.